Overview

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

Status:
Completed
Trial end date:
2019-08-29
Target enrollment:
Participant gender:
Summary
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.
Phase:
Phase 2
Details
Lead Sponsor:
Galera Therapeutics, Inc.
Collaborators:
Clinical Assistance Programs, LLC
Novella Clinical
Treatments:
Avasopasem manganese